FR2549051B1
(fr)
|
1983-06-22 |
1986-05-16 |
Centre Nat Rech Scient |
Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
|
US5262319A
(en)
|
1985-04-19 |
1993-11-16 |
Oncogene Science, Inc. |
Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
|
US5654270A
(en)
|
1988-06-28 |
1997-08-05 |
La Jolla Cancer Research Foundation |
Use of fibromodulin to prevent or reduce dermal scarring
|
JP2887325B2
(ja)
|
1988-06-28 |
1999-04-26 |
ラ ホヤ キャンサー リサーチ ファウンデーション |
デコリンによる細胞増殖の抑制
|
US5705609A
(en)
|
1988-06-28 |
1998-01-06 |
La Jolla Cancer Research Foundation |
Decorin fragments inhibiting cell regulatory factors
|
US5583103A
(en)
|
1988-06-28 |
1996-12-10 |
La Jolla Cancer Research Foundation |
Inhibition of transforming growth factor beta activity
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
DE69030956T2
(de)
|
1989-09-29 |
1998-01-15 |
Jolla Cancer Res Found |
Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix
|
JPH05503003A
(ja)
|
1989-11-22 |
1993-05-27 |
ジェネンテク,インコーポレイテッド |
潜在性関与ペプチドおよびその使用
|
WO1991010727A1
(fr)
|
1990-01-22 |
1991-07-25 |
La Jolla Cancer Research Foundation |
Inhibiteurs de facteurs regulateurs cellulaires
|
US5554655A
(en)
|
1991-09-30 |
1996-09-10 |
Jess G. Thoene |
Method of treating HIV infection
|
JP4124815B2
(ja)
|
1991-10-31 |
2008-07-23 |
ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ |
TGF−β型受容体cDNAおよびその用途
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
JPH07504886A
(ja)
|
1991-11-14 |
1995-06-01 |
ラ ホヤ キャンサー リサーチ ファウンデーション |
細胞調節因子のインヒビターおよびはん痕形成を予防または緩和する方法
|
GB9205800D0
(en)
|
1992-03-17 |
1992-04-29 |
British Tech Group |
Treatment of fibrotic disorders
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
AU5587094A
(en)
|
1992-10-26 |
1994-05-24 |
Kirin Brewery Company, Limited |
Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
|
EP0669833B1
(fr)
|
1992-10-29 |
2002-06-12 |
Celtrix Pharmaceuticals, Inc. |
Fragment du recepteur au tgf-beta de type ii comme agent therapeutique
|
JPH08504577A
(ja)
|
1992-10-30 |
1996-05-21 |
エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ |
TGF−βの制御活性を改変するための組成物および方法
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
WO1994025588A2
(fr)
|
1993-04-30 |
1994-11-10 |
Biognostik Gesellschaft für Biomolekulare Diagnostik mbH |
OLIGONUCLEOTIDES ANTISENS DESTINES AU TRAITEMENT DES EFFETS IMMUNO-SUPPRESSEURS DU FACTEUR TRANSFORMANT DE CROISSANCE-β (TGF-β)
|
AU6984594A
(en)
|
1993-06-15 |
1995-01-17 |
Hun Taeg Chung |
Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
|
AU8016894A
(en)
|
1993-10-15 |
1995-05-04 |
La Jolla Cancer Research Foundation |
Betaglycan polypeptides having tgf-beta binding activity
|
WO1995030900A1
(fr)
|
1994-05-04 |
1995-11-16 |
Mount Sinai Hospital Corporation |
Modulateurs de cytokines de la superfamille des facteurs de croissance transformants beta et methodes pour les doser
|
US5772995A
(en)
|
1994-07-18 |
1998-06-30 |
Sidney Kimmel Cancer Center |
Compositions and methods for enhanced tumor cell immunity in vivo
|
CA2156767A1
(fr)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Agent liant pour facteur de croissance
|
JPH08119984A
(ja)
|
1994-08-31 |
1996-05-14 |
Nkk Corp |
ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
|
US5824655A
(en)
|
1995-02-15 |
1998-10-20 |
The University Of Utah |
Anti-transforming growth factor-β gene therapy
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
WO1997040848A1
(fr)
|
1996-04-30 |
1997-11-06 |
Genzyme Corporation |
Utilisation de la prolactine comme un antagoniste de tgf-beta
|
JPH1067674A
(ja)
|
1996-06-19 |
1998-03-10 |
Advanced Sukin Res Kenkyusho:Kk |
細胞外マトリツクスの異常蓄積抑制剤
|
JP2001511885A
(ja)
|
1996-10-25 |
2001-08-14 |
エチコン・インコーポレーテツド |
抗―線維症剤アッセイ
|
EP0975771B1
(fr)
|
1997-04-18 |
2007-07-11 |
Biogen Idec MA Inc. |
Proteines de fusion contenant le recepteur type ii du tgf-beta et proteines de fusion en tant que region constante d'une immunoglobuline
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US6468522B1
(en)
|
1999-07-22 |
2002-10-22 |
University Of Medicine And Dentistry Of New Jersey |
Controlled release of thioamide moiety-containing therapeutic agents
|
US6521266B1
(en)
|
1999-09-23 |
2003-02-18 |
Morris A. Mann |
Composition for growth hormone production and release, appetite suppression, and methods related thereto
|
GB0102665D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102668D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
WO2002062787A1
(fr)
|
2001-02-02 |
2002-08-15 |
Glaxo Group Limited |
Pyrazoles utilises comme inhibiteurs du tgf
|
ATE291020T1
(de)
|
2001-02-02 |
2005-04-15 |
Smithkline Beecham Corp |
Pyrazolderivate gegen tgf überexprimierung
|
GB0102673D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102672D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
UA76461C2
(en)
|
2001-05-24 |
2006-08-15 |
Lilly Co Eli |
Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
US20050165011A1
(en)
|
2002-05-15 |
2005-07-28 |
Gellibert Francoise J. |
Benzoxazine and benzoxazinone substituted triazoles
|
EP1511738A4
(fr)
|
2002-05-17 |
2007-05-09 |
Scios Inc |
Traitement de troubles de fibro-proliferation au moyen d'inhibiteur de tgf-beta
|
AU2003256783A1
(en)
|
2002-07-25 |
2004-02-16 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
|
GB0217786D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
EP1549316A4
(fr)
|
2002-09-10 |
2008-04-09 |
Scios Inc |
Inhibiteurs de tgf-$g(b)
|
ATE370139T1
(de)
|
2002-09-17 |
2007-09-15 |
Lilly Co Eli |
Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
|
AU2003268155A1
(en)
|
2002-09-19 |
2004-04-08 |
Eli Lilly And Company |
Methods of inhibiting tgf beta with substituted pyrazoles
|
WO2004047818A2
(fr)
|
2002-11-22 |
2004-06-10 |
Scios, Inc. |
UTILISATION D'INHIBITEURS DE TGF-$G(B) POUR CONTREBALANCER LES MODIFICATIONS PATHOLOGIQUES DU TAUX OU DE LA FONCTION DE RECEPTEURS STEROIDIENS/THYROIDIENS
|
WO2004048930A2
(fr)
|
2002-11-22 |
2004-06-10 |
Scios, Inc. |
METHODE PERMETTANT DE CONTRER UN CHANGEMENT PATHOLOGIQUE DANS LA VOIE ss-ADRENERGIQUE
|
US20060079680A1
(en)
|
2002-11-22 |
2006-04-13 |
Eli Lilly And Company Patent Division |
Pyrazoloazepine compounds as pharmaceutical agents
|
UA80571C2
(en)
|
2002-11-22 |
2007-10-10 |
Lilly Co Eli |
Quinolinyl-pyrrolopyrazoles
|
EP1567527A1
(fr)
|
2002-11-27 |
2005-08-31 |
Eli Lilly And Company |
Derives pyrazolo condenses
|
CA2513086A1
(fr)
|
2002-12-19 |
2004-07-08 |
Scios Inc. |
Traitement de l'obesite et de manifestations connexes au moyen d'inhibiteurs tgf-.beta.
|
CL2004000234A1
(es)
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
EP1608631A4
(fr)
|
2003-03-28 |
2008-08-20 |
Scios Inc |
Inhibiteurs bi-cycliques a base de pyrimidine de tgf beta
|
EP1646655A2
(fr)
|
2003-07-09 |
2006-04-19 |
Eli Lilly And Company |
Ligands de tgf-beta1
|
US7232824B2
(en)
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
MXPA06008157A
(es)
|
2003-12-24 |
2007-09-07 |
Johnson & Johnson |
Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
|
US7368445B2
(en)
|
2004-03-01 |
2008-05-06 |
Eli Lilly And Company |
Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
WO2005097832A2
(fr)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Anticorps anti-tgf-$g(b) humanises
|
DE102004019253A1
(de)
|
2004-04-16 |
2005-11-10 |
Codewrights Gmbh |
Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
|
EP1786802A1
(fr)
|
2004-08-31 |
2007-05-23 |
Biogen Idec MA, Inc. |
Pyrimidinylimidazoles utilises comme inhibiteurs de tgf-beta
|
EP1786803A1
(fr)
|
2004-08-31 |
2007-05-23 |
Biogen Idec MA, Inc. |
Pyrimidinylpyrazoles utilises comme inhibiteurs de tgf-beta
|
EP1812450A2
(fr)
|
2004-11-10 |
2007-08-01 |
Eli Lilly And Company |
Inhibiteurs du tgf-beta
|
PL3520815T3
(pl)
|
2005-02-08 |
2022-04-11 |
Genzyme Corporation |
Przeciwciała przeciwko TGFBETA
|
AU2007210005C1
(en)
|
2006-01-27 |
2014-01-23 |
The Regents Of The University Of California |
Enterically coated cysteamine, cystamine and derivatives thereof
|
CA2708004C
(fr)
*
|
2006-12-04 |
2015-12-01 |
Promedior, Inc. |
Therapie conjointe pour le traitement de maladies fibrotiques
|
WO2009070781A1
(fr)
|
2007-11-30 |
2009-06-04 |
The Regents Of The University Of California |
Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
|